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Abstract
Reprogramming of cellular metabolism is an emerging hallmark of neoplastic transformation.
However, it is not known how metabolic gene expression in tumors differs from that in normal
tissues, or whether different tumor types exhibit similar metabolic changes. Here we compare
expression patterns of metabolic genes across 22 diverse types of human tumors. Overall, the
metabolic gene expression program in tumors is similar to that in the corresponding normal
tissues. Although expression changes of some metabolic pathways (e.g., up-regulation of
nucleotide biosynthesis and glycolysis) are frequently observed across tumors, expression changes
of other pathways (e.g., oxidative phosphorylation and the tricarboxylic acid (TCA) cycle) are
very heterogeneous. Our analysis also suggests that the expression changes of major metabolic
processes across tumors can be rationalized in terms of several principal components. On the level
of individual biochemical reactions, many hundreds of metabolic isoenzymes show significant and
tumor-specific expression changes. These isoenzymes are potential targets for anticancer therapy.
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tAll tumors share a common phenotype of uncontrolled cell proliferation. To support the
synthesis of biomass components and to generate energy required for cellular growth, cancer
cells have to reshape the regulatory and functional properties of their metabolic networks.
Over 80 years ago, Otto Warburg1 identified a shift from oxidative to fermentative
metabolism as a common physiological trait of tumor cells. Following this early insight into
cancer metabolism, the main focus of cancer research generally shifted towards the analysis
of signaling, gene-regulatory and genetic perturbations in various tumors2, 3. Recently,
however, there has been a resurgence of interest in cancer metabolism4-6. An important
factor contributing to this renaissance is the observation that many signaling pathways
altered in cancer are key regulators of the human metabolic network5. In addition, the
therapeutic potential of metabolic targets in cancer has also been rediscovered7, 8.
Taking advantage of a large compendium of gene expression profiles that has been
accumulated over the last decade9, 10, in this study we comprehensively analyzed tumor-
induced changes in mRNA expression of human metabolic genes across 22 diverse cancer
types. To minimize confounding metabolic adaptations that may arise from tissue culture
conditions, we analyzed only microarray data obtained from biopsies of primary tumors. We
compared gene expression in tumors and corresponding normal tissues at several conceptual
levels of biochemical organization: at the global network level, at the level of individual
biochemical pathways and at the level of single enzymatic reactions. The focus on the
human metabolic network and the analysis of the large collection of tumor and normal
samples allowed us to gain statistical power and establish significance for many expression
patterns not reported previously.
RESULTS
Global changes in metabolic gene expression
To understand metabolic gene expression in different cancers, we assembled a
comprehensive collection of more than 2500 microarray measurements spanning 22
different tumor types (Online Methods and Supplementary Table 1). Although we analyzed
only expression data obtained using the most comprehensive human expression array
platform (HG U133 Plus 2.0; Supplementary Table 2), comparisons of data for the same
tumor types obtained from independent studies and with different microarray platforms
(Supplementary Table 3) showed a high correlation of expression changes (average
Spearman’s rank correlation coefficient = 0.63), confirming the generality of the observed
expression patterns (see Supplementary Fig. 1).
Using the assembled expression compendium, we first investigated the global shifts in
metabolic gene expression between and within different cancers and their corresponding
normal tissues. For this analysis we used 1421 human genes assigned to metabolic pathways
in the KEGG database11. Using two different measures of divergence between a pair of
expression profiles12, the Euclidean distance and the correlation distance (Online Methods),
we compared global expression patterns between tumors and normal tissues (Supplementary
Table 2). In order to account for batch effect arising due to variations in laboratory
conditions and measurements, the estimated batch contribution was subtracted from
expression distances between expression profiles measured in different studies (Online
Methods).
Relative differences between the distributions are consistent for the two metrics of
expression divergence (Fig. 1 and Supplementary Fig. 2). The expression distance between
tumors and corresponding normal tissues (Tumorn-Normaln) is significantly larger than the
distance between different samples of the same normal tissues (Normaln-Normaln; Mann-
Whitney U test P-value = 10−8; Fig. 1) or between different samples of the same tumors
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t(Tumorn-Tumorn; P-value = 4*10−7). The distance Tumorn-Normaln, however, is
significantly smaller than the distance between different tumors (Tumorn-Tumorm; P-value
= 2*10−7), which in turn is significantly smaller than the distance between different normal
tissues (Normaln-Normalm; P-value < 2*10−16). The average expression distance between
two different tumors is ~82% of the average distance between two different normal tissues,
while the distance between a tumor and a corresponding normal tissue is ~63% of the
distance between two different normal tissues. Consequently, although the metabolic
expression patterns in different tumors become more similar than in corresponding normal
tissues, the general metabolic expression program of the original tissue is mostly retained in
tumors.
Expression changes of individual biochemical pathways
We next analyzed the expression changes associated with individual biochemical pathways
defined in the KEGG database11 (see Supplementary Table 5 for pathway information and
numbering). To identify the patterns of up- and down-regulation for each metabolic
pathway, we determined the significance of its expression changes in the tumor samples
relative to the corresponding normal samples using the Wilcoxon signed-rank test, adjusted
for multiple hypothesis testing (Online Methods). Based on this analysis we calculated the
average fraction of tumor samples in which each metabolic pathway was significantly
(FDR-corrected P-value < 0.05) up-regulated   and down-regulated   across 22 cancer
types (Fig. 2). To assess the statistical significance of the observed pathway behavior, we
computed the null distributions of ( ) and ( ) values for metabolic pathways
highlighted in Fig. 2 and demonstrated statistical significance of the observed patterns
(Online Methods and Supplementary Fig. 3). The general expression patterns observed with
the KEGG pathways were similar to results obtained using the BioCyc pathway
definitions13 (Supplementary Fig. 4a; Supplementary Table 6), suggesting the robustness of
the results with respect to alternative pathway definitions.
As expected, pathways responsible for production of biomass components that are essential
for cell division, such as pyrimidine (18) and purine (16) biosynthesis, are significantly up-
regulated in many tumor samples (Fig. 2). Along with these two pathways, glycolysis (86) is
also significantly up-regulated in many samples, consistent with an enhanced glucose uptake
frequently observed in tumors14. Among other pathways displaying frequent and significant
up-regulation are pathways related to protein synthesis (aminoacyl-tRNA biosynthesis (81))
and glycoprotein biosynthesis (N-glycan biosynthesis (40)). In tumor samples where the
expression of the aforementioned pathways is not significantly changed, the overall
metabolic gene expression was mostly either down-regulated or not significantly changed.
Specifically, this is the case for 72% of tumor samples with no significant change in the
glycolysis pathway expression, 84% of tumor samples with no change in the purine
biosynthesis pathway expression, and 88% of tumor samples with no change in the
pyrimidine biosynthesis pathway expression. The down-regulation of the overall metabolic
gene expression is common for tumors originating from human tissues with significant
metabolic functions (see principal component analysis below).
In contrast to the biosynthesis pathways, pathways responsible for degradation of essential
amino acids (valine, leucine and isoleucine degradation (22)), cofactors (retinol metabolism
(75)), and fatty acids (9) are frequently and significantly down-regulated. Interestingly, two
metabolic pathways that are also consistently down-regulated across various tumors are
xenobiotic (82) and drug (83) metabolism. These processes are responsible for
detoxification and disposal of compounds foreign to the normal biochemistry of the cell.
Several previous studies have shown that polymorphisms in cytochrome P450 genes
correlate with cancer susceptibility in different types of cancer, including those of the lung,
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tbladder and breast15, 16. Although the specific reasons for the decreased expression of
xenobiotic pathways in cancer need to be further investigated, it is possible that this down-
regulation contributes to the increased sensitivity of tumor cells to chemotherapies.
The heterogeneous behavior of the oxidative phosphorylation (15) and the TCA cycle (1)
pathways is also notable (Fig. 2). Interestingly, oxidative phosphorylation shows the most
heterogeneous behavior of all considered metabolic pathways. In brain, colon, kidney,
pancreatic and thyroid cancers genes involved in oxidative phosphorylation are significantly
down-regulated, whereas in breast, leukemia, lung, lymphoma and ovarian cancers these
genes are significantly up-regulated (Supplementary Table 7). This pattern suggests that the
role of oxidative phosphorylation is not universal for all tumors, but possibly reflects the
adaptation of different cancers to tissue-specific physiological conditions such as hypoxia,
nutrient availability, or complement of genetic lesions driving a specific tumor type.
We also explored the heterogeneity of metabolic pathway expression across different
samples of the same (or similar) tumor types. Such an analysis (Online Methods and
Supplementary Fig. 5) showed that oxidative phosphorylation gene expression is not only
heterogeneous between different tumor types, but also frequently varies between samples of
the same tumor. This observation suggests that the activity of oxidative phosphorylation is
influenced not only by the variability of environments across different tumor types, but also
by the specific physiological conditions and/or genetic composition of individual tumors in
each cancer patient. In contrast, other metabolic pathways showed similar expression
patterns across different samples of the same tumor.
Correlation between metabolic pathways and signaling genes
We next investigated correlations between the expression of metabolic pathways and
expression of signaling and regulatory genes frequently involved in tumorigenesis. Although
several previous studies17 demonstrated that correlated expression patterns usually cannot be
equated with regulation causality, i.e. one gene being regulated by the other, significant
correlations could still reveal important functional relationships. To evaluate expression
correlations we used the context likelihood of relatedness (CLR) method18, which is based
on mutual information between expression patterns and controls for specificity of each
discovered relationship (Online Methods), to identify significant interactions (Z-score > 2.0,
Supplementary Table 8) between the 214 non-metabolic genes annotated in the KEGG
signaling/cancer pathways (Supplementary Table 9) and the 87 metabolic pathways
considered in our analysis; significant relationships identified by CLR suggest high mutual
information between expression patterns of the corresponding genes and pathways.
The CLR analysis revealed several interesting relationships. The oxidative phosphorylation
pathway has high mutual information with the hypoxia-inducible factor (HIF1A) and its
negative regulator RBX1. Notably, the oxidative phosphorylation expression is anti-
correlated with the expression of HIF1A, and is correlated with the expression of RBX1.
The observed anti-correlation between oxidative phosphorylation and HIF1A suggests that
the heterogeneity in the expression of oxidative phosphorylation genes (Fig. 2) is likely to be
influenced by tumor oxygen availability. In addition, the mutual information between
HIF1A and glycolysis is not high, likely because HIF1A is involved in the up-regulation of
glycolysis specifically under hypoxia, although many tumors show a strong expression of
oxidative phosphorylation and may not be hypoxic. In contrast, there is significant mutual
information between glycolysis and CDC42, a gene essential for cell cycle progression.
Glycolysis is also strongly correlated with expression of RAS and genes from the MAPK
pathway which have been previously implicated in promoting aerobic glycolysis19. Apart
from glycolysis, CDC42 expression has also high mutual information with other pathways
essential for fast cellular growth (such as purine, pyrimidine, and amino acids biosynthesis).
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tOn the other hand, CDC42 expression is not correlated with the expression of oxidative
phosphorylation, suggesting that in fast growing tumor cells glucose fermentation
dominates. This observation agrees with the results of the principal component analysis
described below.
Principal component analysis of pathway expression changes
Individual metabolic pathways do not function in isolation. In contrast, they display highly
correlated and interdependent patterns of gene expression. Therefore, we used principal
component analysis (PCA)20 to better understand the joint behavior of metabolic pathways
in cancer (Table 1). To reduce noise associated with heterogeneous expression of individual
pathways, we considered the expression changes in the space of nine meta-pathways
representing major metabolic processes (Online Methods). Combined, the first three
principal components were able to capture approximately 85% of the meta-pathway
expression variance.
The first principal component accounts for ~62% of the variance in the meta-pathway
expression changes. As all pathway weights for this component have the same sign and
similar values, it represents an approximately uniform shift in the overall expression of
metabolic genes. The projection of cancer samples onto the plane defined by the first and
second principal components (Supplementary Fig. 6) shows that tumors of the digestive
system (colon, kidney and liver) have high positive shift along this component, suggesting
an overall decrease in metabolic gene expression. In contrast, other tumors (for example,
cervix and lymphomas) show an overall increase in metabolic gene expression. It is likely
that the observed shifts along the first principal component reflect, at least to some extent,
the loss of specific metabolic functions required by the corresponding normal tissues, and
the switch to a metabolic program primarily focused on growth and proliferation. This may
account for the overall decrease in expression of metabolic genes observed in tumors of the
gastrointestinal system that normally have high metabolic gene expression unique to these
differentiated tissues.
Shifts along the second component, explaining ~16% of the expression variance, involve a
change in the expression of glycolysis and nucleotide biosynthesis with a concomitant
opposite change in the expression of three catabolic pathways. Because an increased rate of
nucleotide biosynthesis is especially important during ribosome biogenesis and
chromosomal duplication, our results suggest that dividing cells appear to increasingly rely
on glycolysis. Oxidative phosphorylation is also associated with the second component,
although with a significantly smaller weight than glycolysis (0.21 versus 0.65).
Consequently, along this component glycolysis occurs concurrently with oxidative
phosphorylation. Shifts along the third principal component, explaining ~7% of the
variance, primarily involve a strong change in the expression of oxidative phosphorylation
with a concomitant opposite change in nucleotide biosynthesis. Consequently, a strong up-
regulation of oxidative phosphorylation along this component is likely to be associated with
slower growth rates.
Individual biochemical reactions and isoenzymes
Next, we focused on expression changes associated with individual biochemical reactions,
which form the most basic level in hierarchical organization of the human metabolic
network. We used 2,307 reactions, each associated with at least one known enzyme (Online
Methods) in a model of human metabolism21. In the human metabolic network and in the
networks of other organisms22, a given biochemical reaction is frequently catalyzed by
several different isoenzymes. Isoenzymes may be encoded by separate genes or arise from
splice variants of the same gene. In the network model we used21, ~30% of metabolic
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treactions contain at least two known isoenzymes, and this percentage is even higher (~40%)
for the reactions of central carbon metabolism. Different kinetic and regulatory properties of
isoenzymes are often fine-tuned to meet specific metabolic requirements of various human
tissues22. Owing to metabolic demands and constraints different from those of native tissues,
it is likely that tumors might preferentially express isoenzymes that facilitate survival and
uncontrolled proliferation23, 24.
The heterogeneity of isoenzyme expression across tumors is apparent from the analysis of
central metabolism (Fig. 3). Although genes encoding glycolytic enzymes are frequently up-
regulated in tumors, some isoenzymes are down-regulated in specific cancers. Gene
expression is significantly increased for key enzymes of the pentose phosphate pathway
(PPP), including both the oxidative and non-oxidative branches. Lactate dehydrogenase
(LDH) is also strongly up-regulated, consistent with the high level of lactate production
observed in many tumors25. Frequent down-regulation of the PDH complex likely
contributes to a decreased flux of pyruvate into the TCA cycle observed in many tumors.
The enzymes essential for purine and pyrimidine synthesis, as well as the glutathione
synthetase (GSS)26, are strongly up-regulated. Although glutaminase (GLS) - an enzyme
important for the TCA cycle anaplerosis - is generally down-regulated, it has been
demonstrated that this enzyme is strongly up-regulated post-transcriptionally by the MYC-
mediated suppression of miR-23a/b27. Notably, a recent study28 suggested that an
alternative route for the glutamine-to-glutamate transformation, perhaps through nucleotide
biosynthesis amidotransferases, may play an important role in the glutamine-dependent
anaplerosis. This hypothesis is consistent with a strong up-regulation of the corresponding
enzymes (PPAT and CAD) across tumors.
We investigated changes in relative isoenzyme expression using the Kullback-Leibler (KL)
divergence (Online Methods); the KL divergence is an information-theoretic measure used
to quantify the difference between two probability distributions. For each biochemical
reaction the KL divergence was used to measure shifts in the distribution of isoenzyme
expression between tumors and corresponding normal tissues. This analysis demonstrated
that, on average, the relative expression patterns of isoenzymes are about two times more
similar for different samples of identical normal tissues than for different samples of
identical tumors (Fig. 4a). But more importantly, both of these distances are significantly
smaller than the average distance between isoenzyme expression patterns in tumors and
corresponding normal tissues (Mann-Whitney U test P-value < 2*10−16). This suggests that
for many biochemical reactions neoplastic transformation leads to a significant shift in the
relative expression of isoenzymes.
The human aldolase is a notable example of an enzyme with perturbed expression patterns
in tumors (Fig. 4b). The enzyme has three main isoforms A, B and C. Although aldolase A
(ALDOA) is preferentially expressed in muscle cells, it is also strongly expressed in most
other human tissues. Aldolase B (ALDOB) is preferentially expressed in the liver and
aldolase C (ALDOC) in the brain. The expression analysis shows that the expression of
ALDOA, relative to the other aldolase isoenzymes, significantly increases in tumors.
Notably, ALDOA is also highly expressed in developing embryos29, and therefore may be
particularly suitable for metabolic requirements during fast cell division. Indeed, kcat value
for ALDOA is significantly higher than that of the other isoenzymes30.
Another example of an enzyme with perturbed expression patterns is aconitase. Our analysis
suggests that the citrate efflux from the TCA cycle is likely to be enhanced in cancers by
frequent down-regulation of the mitochondrial isoform of aconitase (ACO2) (Fig. 3a,b).
Cytosolic citrate is used to generate acetyl-CoA, an important precursor required for many
biosynthetic reactions involving lipogenesis31. Inhibition of the mitochondrial aconitase in
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tnormal human tissues32 and yeast33 was previously shown to significantly increase the TCA
citrate efflux. The strong up-regulation of the ATP citrate lyase (ACL) across tumors (Fig.
3) provides additional support for the idea that these changes promote fatty acid biosynthesis
in tumors. A recent study showed that an important route for the synthesis of lipogenic
acetyl-CoA under hypoxia34 is through reductive metabolism of α-ketoglutarate by
cytosolic isocitrate dehydrogenase (IDH1) and cytosolic aconitases (ACO1/ACO3). This
pathway is also supported by the observed expression patterns because in contrast to the
mitochondrial aconitase, the cytoplasmic aconitases are frequently up-regulated in specific
cancers (Fig. 3a), and similar patterns are observed for IDH1 (see below).
To identify specific isoenzymes with frequently perturbed expression profiles, we
calculated, for each isoenzyme in every biochemical reaction, the number of tumors in
which the fractional expression of the isoenzyme among all isoenzymes catalyzing the same
reaction is significantly up-regulated (Online Methods). After correcting for multiple
hypothesis testing (Online Methods), 919 isoenzymes were relatively up-regulated in at least
one tumor type, and 322 were up-regulated in more than 25% of the 22 tumor types
considered in our analysis (Supplementary Table 12).
Expression of enzymes with recurrent tumor mutations
We next investigated expression changes for metabolic genes with known tumor-associated
mutations. Recent sequencing studies have identified recurrent mutations in several genes
associated with the TCA cycle35, 36. Heterozygous somatic mutations in two isoenzymes of
isocitrate dehydrogenase (cytoplasmic IDH1 and mitochondrial IDH2) are frequently
detected in gliomas and acute myeloid leukemia (AML). These gain-of-function mutations
affect the IDH active site, and make it possible for the mutated enzymes to catalyze the
conversion of α-ketoglutarate to 2-hydroxyglutarate (2HG), which has been proposed to
promote cancer development37. Our analysis reveals that IDH1 and IDH2 isoenzymes are
frequently up-regulated in cancers (Fig. 3b), but the expression of the other isocitrate
dehydrogenase isoenzyme IDH3 (not commonly mutated in tumors) is not significantly
perturbed. A detailed analysis of IDH expression across cancers (Supplementary Table 13)
demonstrated that the up-regulation P-values of IDH1 and IDH2 for the three brain cancers
and AML are among the five most significant of all considered tumor types. Recent
sequencing efforts38 also demonstrated the presence of similar IDH active site mutations in
peripheral T-cell lymphoma, another tumor in our study with significant up-regulation of
IDH expression (Supplementary Table 13).
Germline and somatic loss-of-function mutations in fumarate hydratase (FH) and three
subunits of succinate dehydrogenase (SDHB, SDHC, SDHD) are also observed in several
tumors including renal cell carcinoma (RCC)36, 39. These deleterious mutations lead to the
accumulation of the metabolites fumarate and succinate that regulate hypoxia-inducible
factor (HIF) protein levels and chromatin state to influence tumor growth40, 41. We found
that the SDH subunits (SDHB, SDHC, SDHD) and FH are strongly down-regulated
specifically in RCC (Supplementary Tables 14 and 15). The only cancer in our analysis with
a more significant down-regulation is colorectal cancer, in which decreased expression of
SDH was reported previously42. Although no somatic mutation in SDH or FH has been
observed in colorectal cancer43, 44, the significant decrease in their expression, similar to
deleterious mutations in other tumors, is likely to cause mitochondrial efflux of the tumor-
promoting TCA cycle intermediates and contribute to tumorigenesis.
Analysis of TCA cycle metabolites in colon cancer
To confirm our computational prediction about the TCA cycle intermediates in colon cancer,
we measured and analyzed concentrations of specific metabolites from 10 colon cancer
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tpatients. The metabolite levels were obtained using GC/MS or LC/MS (Online Methods)
and contained matched tumor and normal samples from each patient.
Consistent with significant down-regulation of oxidative phosphorylation pathway genes
(Wilcoxon signed-rank test P-value = 10−9, Supplementary Table 7) and down-regulation of
the PDH complex (P-value = 0.02) that controls the majority of glucose carbon flux into the
TCA cycle, there is a significant decrease in the citrate concentration (Wilcoxon signed-rank
test P-value = 0.01) in tumor samples and a concomitant increase in the lactate concentration
(P-value = 0.001). Despite a large decrease in the citrate concentration (average decrease
~65%, median ~90%), the average concentration of a downstream metabolite succinate is
only 33% lower than normal and the average concentration of fumarate is more than 50%
higher than in normal samples (P-value = 0.03). This pattern of concentration changes is
consistent with the significant down-regulation of the FH and SDH enzymes observed in
colon cancer expression profiles. Such a down-regulation should lead to a significant
increase, relative to the available citrate, in the concentration of their substrates fumarate and
succinate. Notably, it was previously demonstrated40 that even a small increase in fumarate
concentration is enough to stabilize HIF1A by inhibition of the α-ketoglutarate-
dioxygenases regulating its degradation41. The average increase in fumarate concentration
(~50%) was about half of the amount observed previously for bi-allelic deletions of the FH
enzyme (~90%)40. For four patients in our samples, fumarate concentration was >50%
higher than in matched normal samples and for three it was >100% higher. Consequently,
the expression changes we observed should mimic the effects of cancer-associated
heterozygous FH mutations in a substantial fraction of colon cancer patients.
DISCUSSION
Reprogramming of the metabolic network is now considered to be a hallmark of neoplastic
transformation2. An overarching conclusion of our study is that cancer-induced changes in
the expression of metabolic genes are very heterogeneous across different tumor types, i.e.
there is no uniform metabolic transformation associated with all tumors. We observe
heterogeneous behavior at all levels of biochemical organization, from global expression
patterns to metabolic pathways to individual reactions and corresponding isoenzymes. The
heterogeneous behavior of cancer metabolism is reminiscent of the high variability observed
between tumors in terms of genetic and expression changes in signaling and regulatory
pathways3.
Notably, despite the heterogeneity between cancers, the metabolic expression changes
associated with individual tumors are not random. On the contrary, many of the observed
changes are reproducible in independent samples of the same tumors. We can discern
several principles unifying the observed tumor-induced expression perturbations. First,
tumors often retain a significant imprint of the metabolic expression patterns present in the
corresponding native tissues. This may be a consequence of similar local environments or
indicate a relative rigidity of the metabolic expression program established in the original
tissue. Such behavior is conceptually similar to the minimization of metabolic adjustments
(MOMA) principle observed in microbial metabolism following genetic perturbations45.
Second, a large fraction of the variance in the expression of major biochemical processes
can be rationalized in terms of several principal components, representing important
expression modes for key metabolic processes. Although, in agreement with physiological
studies14, 46, we do not observe universal up- or down-regulation for genes associated with
oxidative phosphorylation, the collective expression changes along the second and third
principal components suggest that fast-growing cells increasingly rely on glucose
fermentation. Third, we find that many hundreds of isoenzymes show significant and tumor-
specific expression changes. A substantial fraction of these changes are likely to be
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tfunctionally important and, at least in some cases, mimic (as in the case of SDH and FH) or
possibly enhance (as in the case of IDH) the effects of recurrent tumor-promoting genetic
mutations.
Beyond understanding of tumor-induced expression changes, we believe that our analysis
has important implications for the development of anticancer therapeutics. Functionally
important isoenzymes with cancer-specific expression changes can potentially serve as drug
targets. The possibility of targeting specific isoenzymes, such as GLS18 and PKM27, has
already been demonstrated, but our analysis suggests that many other potential targets may
be pursued in a similar way. Due to the tumor-specific nature of the observed expression
patterns, such targeting will require a focused analysis and understanding of essential
metabolic transformations in each specific cancer type.
ONLINE METHODS
Microarray expression datasets
Published gene expression datasets were assembled from the GEO9 and ArrayExpress10
databases (Supplementary Table 1). Unless specified otherwise, we analyzed only
expression data obtained using the most comprehensive human expression array platform
(HG U133 Plus 2.0; Supplementary Table 2). For calculations involving global network
properties and comparisons of expression data between different studies (Fig. 1), samples
from all datasets were processed together. For all other calculations, tumor and normal
samples from the same study were processed together. The affyQCReport package from
Bioconductor (www.bioconductor.org) was used to search for poor quality chips. For
GeneChip arrays that passed Quality Control (QC) checks, we used the GCRMA
algorithm47 from Bioconductor to perform quantile normalization and extract gene
expression values on the log2 scale.
Calculation of differential expression (DE) for metabolic genes
Separately for each dataset, the Bioconductor method limma48, which is based on a
modified t-statistic, was used to analyze differences between tumor samples and
corresponding normal samples. Using the method we calculated the differential expression
for each metabolic gene on the log2 scale. The differential expression P-values were
adjusted for multiple hypothesis testing using Benjamini and Hochberg’s method49,
controlling False Discovery Rate (FDR) at 5%.
Calculation of the global divergence between a pair of expression profiles
Two different measures of divergence between a pair of expression profiles were used in our
study: (1) The Euclidean distance,  ,
where xi and yi are the expression of gene i over two expression profiles with p and q
samples (x1, x2 ,…, xp ), (y1, y2 ,…, yq ), n = 1421 is the number of genes assigned to at
least one metabolic pathway in the KEGG database, (2) The correlation-based distance dcor
= 1–r(Average log 2 x), Average(log2 y)), where r is the Spearman’s rank correlation
coefficient between average log2 expression values of corresponding genes in the two
expression profiles.
When comparing datasets across different studies it is important to consider batch effect
arising due to variations in laboratory conditions and measurements. To explore and address
batch effect, we collected a set of microarray expression data for the same tissues/tumor
types from multiple independent studies (Supplementary Table 4). All samples in
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tSupplementary Table 4 were processed and normalized together. To estimate the influence
of the batch effect, we calculated d1, the average expression distance between tumors
(Tumorn) and corresponding normal tissues (Normaln) measured in different studies, and d2,
the average expression distance between tumors (Tumorn) and corresponding normal tissues
(Normaln) measured in the same studies. The difference ( d1 – d2 ) represents the average
batch effect due to comparisons across different studies. To account for the batch effect the
difference ( d1 – d2 ) was subtracted from all expression distances calculated between
different studies.
Identification of metabolic pathways with significant expression changes
We used two different approaches to identify metabolic pathways with significant
expression changes. The two approaches resulted in very similar results. In the first
approach, which was used for all calculations presented in the paper, for each gene a, we
calculated its expression change in tumor sample i relative to the corresponding normal
samples,  , where   is the expression in tumor sample i, and
ya is the expression in the s corresponding normal samples (y1 ,y2 ,…, ys ). Wilcoxon
signed-rank test of ΔE for all genes within a metabolic pathway was then used to determine
the significance of up- or down- regulation of the pathway in that tumor sample. In the
second approach, for each gene a, we calculated the z-score of its expression in tumor
sample i relative to the distribution of its expression values in the s corresponding normal
samples,  , where   is the standard
deviation. Wilcoxon signed-rank test of z was then used to determine the significance of up-
or down- regulation of each pathway in that tumor sample. The pathway expression
heterogeneity based on the second approach is shown in Supplementary Fig. 4c.
Statistical significance of the observed metabolic pathway expression patterns
We used randomized expression data to assess the statistical significance of the reported
pathway expression patterns (Fig. 2). To generate the null distributions for the ( ) and
( ) values we used the real expression data and randomly permuted metabolic gene
labels while preserving the pathway sizes. We then calculated the null distributions using the
same procedure as the one applied to the real data. Supplementary Fig. 3 shows the null
distributions for the 10 top-regulated pathways (pathways with highest ( ) values in Fig.
2) based on 1000 random permutations of the expression data.
Pathway expression heterogeneity across tumor samples of the same tumor type
To investigate the pathway expression heterogeneity across tumor samples of the same
tumor type, we introduced a pathway-specific heterogeneity metric  , where
n is the fraction of tumor samples of a certain tumor type in which the pathway is
significantly up-regulated, and m is the fraction of samples in which the pathway is
significantly down-regulated. According to this definition, for high H values the pathway
shows consistent expression changes across different samples of the same tumor type, i.e.
the pathway is mostly up-regulated or mostly down-regulated. On the other hand, for small
H values the pathway expression is variable, i.e. in some tumor samples the pathway is
significantly up-regulated, while in other samples of the same tumor type the pathway is
significantly down-regulated. The distribution of H values across 22 tumor types or 16
tumor types of different tissue-of-origin for 10 top-regulated pathways (pathways with
highest (n+m) values), is shown in Supplementary Fig. 5. The 16 tumors types of different
tissue-of-origin were obtained from 22 tumor types by considering samples of the three
types of brain cancers, the two types of breast cancers and the four types of lymphomas
together, respectively.
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expression of non-metabolic cancer/signaling genes
The context likelihood of relatedness (CLR) method18 is based on mutual information
between expression profiles. CLR was used to identify significant relationships between 214
non-metabolic cancer/signaling genes annotated in the KEGG database and the 87 KEGG
metabolic pathways (Supplementary Table 5). The set of 214 non-metabolic cancer/
signaling genes was assembled using the following two criteria: (1) genes either from the 14
KEGG cancer or 25 KEGG signaling pathways (see Supplementary Table 9), and (2) not
within any of the 87 KEGG metabolic pathways. For each gene a in each tumor sample i, the
expression change   was calculated. And the mutual information (MI) between each non-
metabolic cancer/signaling gene i and each metabolic pathway j was calculated across all
tumor samples in our study:  , where nj is the number of genes
within the a pathway j. All mutual information values were computed using 10 bins of ΔE ;
the calculated values were not sensitive to the exact number of bins used. The CLR
interaction Z-score for each gene i and pathway j pair   was calculated using
(I) the z-score (zi ) of MIij relative to the distribution of {MIi,1, MIi,2,…,MIi,87 }, and (II) the
z-score ( zj ) of MIij relative to the distribution of {MI1,j,MI2,j,…,MI214,j }. In
Supplementary Table 8 we show the identified significant relationships (with Z-score > 2.0)
for each metabolic pathway.
Principal component analysis
The nine meta-pathways used for the principal component analysis were compiled by
combining genes from corresponding metabolic pathways in the KEGG and BioCyc
databases. To perform the principal component analysis (PCA), we calculated the p-by-q
matrix D for tumor-to-normal expression changes of the meta-pathways, where p = 466 (the
total number of tumor samples in our study) and q = 9 (the number of meta-pathways). We
used two different approaches to calculate D. The two approaches resulted in very similar
principal components. In the first approach, the (i, j)-element of the matrix Dij is the average
gene-specific expression changes in tumor sample i across nj genes within meta-pathway j:
. In the second approach, Dij is the average gene-specific z-scores:
. Principal components were then obtained using the covariance method, i.e.
we first centered the columns of D by subtracting the column means, and then calculated a
covariance matrix based on D. The covariance matrix was then diagonalized and the
eigenvectors and eigenvalues were calculated.
The results of the PCA analysis based on the first approach are shown in Table 1 and the
results based on the second approach in Supplementary Table 10. We also explored the
influence of genes shared between meta-pathways on the PCA results. The results obtained
when all overlapping genes were excluded (Supplementary Table 11) were very similar to
the results with all meta-pathway genes.
Human metabolic annotations used for isoenzyme expression analysis
The human metabolic network compiled by Duarte et al.21 was used for isoenzyme
expression analysis. The network contains 1496 genes, 2712 compartment-specific
metabolites, and 3743 internal and exchange reactions. In the analysis we used 2307
network reactions that are associated with at least one known metabolic gene. Proteins that
are responsible for catalysis of identical reactions and are not members of the same complex
were considered as isoenzymes. In total, the network by Duarte et al. contains 667 metabolic
reactions with at least two isoenzymes.
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The Kullback-Leibler (KL) divergence was used to quantify the changes in the relative
expression of isoenzymes for pairs of expression profiles. For each sample, the fractional
expression of a particular isoenzyme i was first calculated   (n is the number of
isoenzymes catalyzing the reaction and xi is the expression value of the isoenzyme i). The
flexmix package in R was then used to estimate the Kullback-Leibler divergence between
the discrete distributions {m(f1),m(f2),…,m(fn)} and {g(f1),g(f2),…,g(fn)}, where m(f) and
g(f) are the averages of the two expression profiles over p and q samples (x1 ,x2 ,…, xp ),
(x1 ,x2 ,…, xq ).
Identification of isoenzymes preferentially expressed in specific tumors
For each considered isoenzyme we used the non-parametric Mann-Whitney U test to
determine the significance of its fractional expression changes in the tumor samples relative
to the normal samples. Specifically, for an isoenzyme i we calculated its fractional
expression among all isoenzymes associated with the same reaction:  , where n is
the number of isoenzymes catalyzing the same reaction, and xi is the expression value of the
isoenzyme i. We then used the Mann-Whitney U statistic to test the hypothesis that the
distribution of fi values for tumor samples associated with a particular cancer type has
significantly larger mean than the distribution of fi values for the corresponding normal
samples. All the P-values were FDR-adjusted at 5% considering the total number of tested
hypothesis, 22704 (1032 isoenzymes times 22 cancer types). The isoenzymes passing the
significance threshold (P-value < 0.05) are reported in Supplementary Table 12. We
confirmed the isoenzyme results using an independently collected expression data from the
TCGA consortium50; for the confirmation we used four tumor types from TCGA
(glioblastoma multiforme, breast invasive carcinoma, colon adenocarcinoma, ovarian serous
cystadenocarcinoma). Using the same tumor type 70% of the isoenzymes in Supplementary
Table 12 showed the same up-regulation behavior in TCGA as in the dataset analyzed in the
paper.
Statistical significance and multiple hypothesis testing
For pathway and isoenzyme calculations involving multiple hypothesis testing, all the
corresponding P-values were adjusted with the BH procedure49 (using the multtest package
in R) to control the false discovery rate (FDR) at 0.05. The FDR-corrected P-values were
used to analyze statistical significances, and unless specified otherwise, significance was
reported for the adjusted P-value < 0.05.
Quantitative metabolite profiling of TCA cycle intermediates in colon cancer. Sample
collection and metabolite extraction
Tumors and surrounding grossly normal-appearing tissues were obtained from 10 colon
cancer patients after surgical treatment. The excised tissues were immediately stored at
−80°C. Samples were extracted and prepared for analysis using Metabolon’s standard
solvent extraction method. The extracted samples were split into equal parts for analysis on
the GC/MS and LC/MS platforms.
GC/MS
The samples destined for GC/MS analysis were re-dried under vacuum desiccation for a
minimum of 24 hours prior to being derivatized under dried nitrogen using bistrimethyl-
silyltriflouroacetamide (BSTFA). The GC column was 5% phenyl and the temperature ramp
is from 40° to 300° C in a 16 minute period. Samples were analyzed on a Thermo-Finnigan
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tTrace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact
ionization.
LC/MS
The LC/MS portion of the platform was based on a Waters ACQUITY UPLC and a
Thermo-Finnigan LTQ mass spectrometer, which consisted of an electrospray ionization
(ESI) source and linear ion-trap (LIT) mass analyzer. The sample extract was split into two
aliquots, dried, then reconstituted in acidic or basic LC-compatible solvents, each of which
contained 11 or more injection standards at fixed concentrations. One aliquot was analyzed
using acidic positive ion optimized conditions and the other using basic negative ion
optimized conditions in two independent injections using separate dedicated columns.
Extracts reconstituted in acidic conditions were gradient eluted using water and methanol
both containing 0.1% Formic acid, while the basic extracts, which also used water/methanol,
contained 6.5 mM Ammonium Bicarbonate. The MS analysis alternated between MS and
data-dependent MS2 scans using dynamic exclusion.
Data extraction and compound identification
The data extraction of the raw mass spec data files yielded information that could be loaded
into a relational database and manipulated without resorting to BLOB manipulation. Once in
the database the information was examined and appropriate QC limits were imposed. Peaks
were identified using Metabolon’s proprietary peak integration software, and component
parts were stored in a separate and specifically designed complex data structure. TCA cycle
intermediates were identified by comparison to library entries of purified standards. The
combination of chromatographic properties and mass spectra gave an indication of a match
to the specific compound or an isobaric entity. The collected metabolite data is presented in
Supplementary Table 16.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Global differences in metabolic gene expression between tumors and normal tissues. Colors
represent distributions of the Euclidean (RMSD) expression distance between different
samples of identical normal tissues (Normaln-Normaln, magenta), different samples of
identical tumors (Tumorn-Tumorn, cyan), tumors and corresponding normal tissues
(Tumorn-Normaln, blue), different tumors (Tumorn-Tumorm, green), and different normal
tissues (Normaln-Normalm, red). The distributions shown in the figure were binned for
display purposes only. Inset summarizes the average distances between pairs of tissues as a
percentage of the average distance between two different normal tissues.
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Expression of individual metabolic pathways in tumors. The biochemical pathways defined
in the KEGG database (see Supplementary Table 5 for pathway numbering) are shown in
the coordinates of ( , horizontal axis) and ( , vertical axis), where   is the average
fraction of tumor samples in which a pathway is significantly up-regulated, and   is the
average fraction in which a pathway is significantly down-regulated. The averages   and 
were calculated across all 22 tumors. The up- (down-) regulation significance was
determined using Wilcoxon signed-rank test (FDR-corrected P-value < 0.05, see
Supplementary Fig. 4b for the same analysis with FDR = 0.2). Several pathways are
highlighted using different colors. The dashed lines demarcate the region where   is less
than 20% of   and are shown for visualization purposes only. Metabolic pathways
without significant expression changes are primarily clustered on the left of the figure.
Pathways that are often significantly up-regulated (high   values) occupy positions in the
upper right corner, while pathways that are primarily down-regulated (high   values)
occupy positions in the lower right corner. Highly heterogeneous pathways that show, in
different tumors, both significant up- and down-regulation are clustered on the right near
zero on the vertical axis.
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Tumor-induced mRNA expression changes for individual biochemical reactions in central
metabolism. (a) Each metabolic reaction is marked with the number of tumors (out of 22
considered in our analysis) in which at least one isoenzyme catalyzing the corresponding
reaction is significantly (FDR-corrected P-value < 0.05) up-regulated (red) and down-
regulated (blue). (b) Reactions that are significantly up-regulated (red triangles) or down-
regulated (blue triangles) when all isoenzymes and members of the corresponding protein
complexes are considered together across all tumors (deep red or deep blue, FDR-corrected
P-value < 0.05; light red or light blue, FDR-corrected P-value < 0.1). If unmarked, no
statistically significant change in mRNA expression was detected.
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Cancer-induced changes in relative isoenzyme expression. (a) The Kullback-Leibler (KL)
divergence was used to characterize differences in the relative expression of isoenzymes for
all biochemical reactions with multiple isoenzymes. Colors represent distributions of the KL
divergence in isoenzyme expression between different samples of identical normal tissues
(Normaln-Normaln, blue), different samples of identical tumors (Tumorn-Tumorn, red), and
tumors and corresponding normal tissues (Tumorn-Normaln, green). Inset summarizes the
average KL divergences between pairs of tissues as a percentage of the average KL
divergence between different samples of identical normal tissues. (b) Relative expression of
the aldolase isoenzymes for kidney, liver, stomach, brain (GBM) tumors and the
corresponding normal tissues.
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Concentration changes for measured metabolites of the TCA cycle. The metabolite data,
obtained from 10 colon cancer patients, contained matched normal and tumor samples.
Every point in the figure represents the log2 ratio of tumor-to-normal concentration change
for a single patient. The P-values above double arrows (in black) indicate the Wilcoxon
signed-rank test significance of changes between consecutive metabolites. The P-values
below metabolite names (in colors) indicate the Wilcoxon signed-rank test significance of
changes between matched normal and tumor samples. The inset shows the measured
metabolites in the context of the TCA cycle.
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Table 1
Principal component analysis (PCA) of gene expression in major metabolic processes. The PCA was
performed using the average expression changes of genes forming nine metapathways representing major
biochemical processes. The pathway weights indicate the relative contribution of each meta-pathway to the
principal components; weights with identical signs indicate correlated contributions of pathways to a
component, while weights with opposite signs indicate anti-correlated contributions. The table show the PCA
weights of each meta-pathway for the first three principal components. The first three principal components
explain ~62%, ~16% and ~7% of variance in expression data, respectively
Variables Number of genes involved
in each pathway
Weights in the 1st
component
Weights in the 2nd
component
Weights in the 3rd
component
Oxidative phosphorylation 135 −0.40 0.21 0.67
Glycolysis 24 −0.33 0.65 −0.01
Citric acid cycle 21 −0.50 −0.10 0.02
Amino acids biosynthesis 70 −0.27 −0.11 −0.17
Fatty acids and lipids biosynthesis 66 −0.28 0.05 0.09
Nucleotides and nucleosides biosynthesis 54 −0.35 0.34 −0.67
Amino acids degradation 123 −0.31 −0.40 −0.15
Fatty acids and lipids degradation 80 −0.22 −0.35 0.17
Nucleotides and nucleosides degradation 9 −0.26 −0.34 −0.04
Proportion of variance explained by each
component − 0.62 0.16 0.07
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